We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ananda Pharma Plc | AQSE:ANA | Aquis Stock Exchange | Ordinary Share | GB00BDQPXQ60 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.425 | 0.37 | 0.43 | 0.4298 | 0.40 | 0.425 | 2,602,559 | 16:29:53 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:5279R All Nippon Airways Co Ld 31 October 2003 Six months ended September 30, 2003 Consolidated financial results All Nippon Airways Co., Ltd. (9202) ANA reports consolidated financial results for the interim of FY2003 1. Consolidated financial highlights for the period ended September 30, 2003 (1) Summary of consolidated operating results Yen (Millions) Interim FY2003 Year on year Interim FY2002 Year on year (%) FY2002 (%) Operating revenues 608,341 (2.2) 622,134 (2.6) 1,215,909 Operating income (loss) 14,460 (3.1) 14,928 (66.2) (2,597) Recurring profit (loss) 14,310 138.0 6,012 (81.2) (17,236) Net income (loss) 20,570 - (8,105) - (28,256) Net income (loss) per 13.42yen (5.28yen) (18.42yen) share Diluted net income per 12.59yen - - share Gain (loss) on equity (64) (105) 364 method Average number of shares of outstanding during the period 1,532,814,664 1,534,237,705 1,533,940,445 (consolidated) Note: Changes in the accounting policy during the period: none (2) Summary of consolidated financial positions Yen (Millions) Interim FY2003 Interim FY2002 FY2002 (As of September 30, 2003) (As of September 30, 2002) (As of March 31, 2003) Total assets 1,491,138 1,455,578 1,442,573 Shareholdersf equity 144,510 141,624 121,954 Shareholdersf equity ratio 9.7% 9.7% 8.5% Shareholdersf equity per 94.25yen 92.32yen 79.57yen share Number of shares of outstanding at balance sheet date 1,533,325,206 1,533,981,551 1,532,694,609 (consolidated) (3) Summary of consolidated cash flows Yen (Millions) Interim FY2003 Interim FY2002 FY2002 Cash flows from operating activities 34,144 66,109 85,952 Cash flows from investing activities (37,990) 13,996 (52,478) Cash flows from financing activities 17,374 (70,006) (63,364) Cash and cash equivalents at the end of the period 171,468 197,300 158,121 (4) Scope of consolidation and application of the equity method Number of consolidated subsidiaries: 103 Number of non-consolidated subsidiaries accounted for by the equity method: 6 Number of affiliates accounted for by the equity method: 19 (5) Change of scope of consolidation and application of the equity method Consolidation Equity method Newly added - 1 Excluded 6 - 2. Forecast of consolidated operating results for the period ending March 31, 2004 Yen (Millions) Operating revenues 1,218,000 Recurring profit (loss) 14,000 Net income (loss) 17,500 Note: Forecast of net income per share: 11.41yen This forecast is made based on (1) the information available to ANA as of the date of publication of this material and (2) assumptions as of the same date with respect to the various factors which might have impact on the future financial result of ANA. The reader should be aware that actual results could differ materially due to various factors with reference to the supporting data. This information is provided by RNS The company news service from the London Stock Exchange END IR FDWSAFSDSEIS
1 Year Ananda Pharma Chart |
1 Month Ananda Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions